Analysis of the Radiopharmaceuticals Used in PET/CT to Evaluate Hypoxic Cells
| Articles mentioning… | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tracer | Head andneck tumors | Lipophilic/hydrophilic | LogP | Radiopharmaceuticalsensitive to acute hypoxiadetection | Image acquisitiontime after administration | SUV | Nonhypoxic cell clearance velocity | Reproducibility ofradiopharmaceutical | Excretionroute |
| 18F-FMISO | (23,29,35,44,48) | Lipophilic(23,24,29) | -0.42 to −0.38 (50) | None | 2–4 h(9,20,23,35,51) | None | ↓ (51) | None | Hepatobiliary and gastrointestinal (50) |
| 18F-FETNIM | (29,44) | Hydrophilic (24,38) | None | None | None | None | ↑ (20) | None | Rapid renal and low hepatic (24,38) |
| 18F-FAZA | (29,44) | Hydrophilic (24,29) | 0.04 (50) | (27) | 2–3 h (18,27) | ↑ (54) | ↑ (4,29,54) | None | None |
| 18F-HX4 | (29) | Hydrophilic (24,29) | −0.71 to −0.67 (50) | (27) | 1.5–4 h (18,27) | None | ↑ (50) | None | Intestinal, low hepatic.mostly renal (24,38,50) |
| 18F-RP-170 | None | None | None | None | None | ↑ (24) | None | None | None |
| 18F-FPIMO | None | None | None | None | None | ↓ (54) | None | None | Hepatic and renal (54) |
| 18F-EF5 | (29 , 56) | Lipophilic (20,24) | None | None | 3 h (56) | None | None | ↑ (17) | None |
| 62Cu-ATSM | (29) | Neutral lipophilic (41,43) | None | None | 10–15 min(40,41) | None | ↑ (41–43) | None | None |
| 64Cu-ATSM | (29) | Neutral lipophilic (20,24) | None | None | 10–15 min (20,24) | None | ↑ (29,38) | None | Reduced renal (high liver accumulation) (58) |
↑ = increased; ↓= decreased.